Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell(TM)'s Excellent Results

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), an autologous (patient's own stem cells) regenerative medicine company is pleased to announce the VesCell™ Phase I Longevity Clinical Trial protocol has been drafted . The longevity protocol represents an important milestone in Hemostemix's strategy to expand the clinical application of VesCell™ beyond the treatment of cardiovascular diseases, toward improving healthspan —the number of years people enjoy health, pain free, remaining active, strong, independent, mentally sharp and cognitively competent.

The commercial Phase I clinical trial is designed to study and leverage how VesCell™ improves multiple measures of healthspan, including patient reported quality of life, muscle mass (cardiac performance), improved cognition, immune system health, physical performance, and functional independence.

Hemostemix' Excellent Phase I Quality of Life Survey Results In Hemostemix' ischemic Phase I cardiomyopathy study, 30 patients with paired SF-36 assessments at three and six months showed increases across all eight quality-of-life domains, with statistically significant improvements: 58% improvement In Physical Functioning from 37.83 to 60.09—an increase of 22.26 points, p<0.001; 92% improvement in Role Limitations due to physical health from 31.89 to 61.21—up 29.32, p<0.001; 56% improvement in General Health from 34.79 to 54.57—up 19.78 points, p<0.001; 48.6% improvement in Vitality from 39.58 to 58.82—up 19.24 points, p=0.001; 24% improvement in Social Functioning from 60.83 to 75.42—up 14.59 points, p=0.014. 30.8% improvement in the Physical Component Summary, from 30.75 to 40.21, up 9.46 points, p<0.001

SF 36 Survey and P Values Explained The SF-36 is a validated questionnaire that measures changes in quality of life based on physical health, pain, energy, emotional well-being and ability to perform everyday activities. A result of p<0.05 means there is less than a 5% probability that the observed difference arose from random variation alone, the conventional threshold for statistical significance. In Hemostemix' clinical trials, findings less than p<0.05 provide increasingly strong evidence that the improvements were not due to chance.

Thomas Smeenk, CEO, said: "Given our results exactly mirror the requirements to win a nine figure longevity competition, a commercial VesCell™-based longevity clinical trial in healthy adults makes sense. Why wait for disease-related degeneration when VesCell™ is designed to restore circulation, cognition, increase exercise capacity, and improve the immune system by reducing inflammation?"

The Longevity trial is designed to generate clinical evidence that support participation in Healthspan competitions, some which offer up to US$101 million in prize funding to accelerate innovations that improve healthy human aging. One such competition measures longevity as increases in muscle capacity (6 minute walk test), cognition, and immune system function, which Hemostemix's results mirror.

Improved 6 Minute Walk Test as a Result of Increased Heart Function The six-minute walk test measures the increased (decreased) distance a person can walk on a flat surface in six minutes before and after treatment. In the Phase I Angina trial, mean six-minute walk distance increased 81.3 meters post treatment at 3 months, p<0.001 and remained as an increase of 79.6 meters 6 months post treatment from baseline, p<0.001 (Tresukosol et al., 2006). In the same study, the proportion of heart that was suffering from inadequate blood circulation improved 45.3% Myocardial perfusion defects decreased 37.9% at three months, p<0.004, and decreased by 45.3% at six months from baseline, p<0.005 (Tresukosol et al., 2006). I mproved cardiac function is consistent with an 80 meter improvement i...